How strategic collaboration can accelerate innovation:
- Moving from transactional execution to consultative partnership
- How CROs can become strategic problem solvers, not just service providers
- Building trust transparency and shared accountability
Archives: Agenda
Lunch and networking
PATIENT ADVOCATE PERSPECTIVE – How the right targeted communication and navigation favorably impacts clinical trial recruiting that is commensurate with the burden of disease
- The factors/barriers for why patients don’t readily participate in clinical trials and how to address them
- Why targeted culturally humble communication is necessary for “marketing” clinical trials
- The benefits of navigation to retain patients
- Success story examples
Chair’s closing remarks
END OF DAY 1 AND NETWORKING DRINKS
Best 3 LinkedIn posts from day 1 with hashtag #CTO and @Clinical Trials in Oncology Event Series tagged will win a prize in day 2 morning’s prize draw during chair’s opening remarks. Deadline end of drinks reception day 1. You must be present to win!
SITE PERSPECTIVE: Accelerating study activation: Legal innovation and site-sponsor collaboration in practice
Faraz Siddiqui is an experienced healthcare attorney who negotiates clinical research agreements on behalf of Memorial Sloan Kettering with pharmaceutical companies and CROs. His session will cover:
- How Sponsors can collaborate with sites on innovations to accelerate trial activation, in an environment of limited budgets and high study volume.
- Implementation of site-driven legal innovations to streamline contract negotiation frameworks.
- Case Study of MSK’s Early Drug Development (EDD)’s cross-functional pilot (regulatory, legal, operations, finance) to address bottlenecks and improve efficiency in study activation
Perspectives and emerging considerations for use of tissue biopsies in clinical trials
- Why tissue biopsies are sometimes essential in clinical trials for novel therapeutics
- Question-based framework to align tissue collection and analysis with clinical trial objectives and timelines
- Emerging biomarker technologies including digital pathology, artificial intelligence, and multiplex spatial biology
Innovating clinical trial design without overcomplicating it
- Selecting fit-for-purpose digital endpoints for modern trial design
- Identifying where digital endpoints create meaningful value and understanding why adoption remains limited in many studies
- Case study: current clinical study with multiple digital endpoints. From design to data.
- Practical lessons from real-world trial designs: successes, challenges, and implementation pitfalls
Bringing cell and gene therapies to oncology community sites: Why (and how) the time is now
- The continued development and commercial feasibility of cell and gene therapies require access to the community setting
- With current downward pressures on academic research institutions in the U.S., community sites are ideally primed to help support and drive this clinical development
- Through innovative, strategic positioning of sites, sponsors and vendors, community access to these therapies can accelerate development through increased data collection